⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935586 | 1.00 | — | — | |
| SCHEMBL11917921 | 1.00 | — | — | |
| SCHEMBL14285557 | 0.86 | — | — | |
| SCHEMBL94282 | 0.86 | — | — | |
| SCHEMBL8624649 | 0.85 | IRAK4 (0.40) | — | |
| Butyl Alcohol SCHEMBL28361945 | 0.85 | PRKCA (0.39) | — | |
| SCHEMBL6443714 | 0.85 | BRD4 (0.36) | — | |
| Methacrylic Acid SCHEMBL11888730 | 0.84 | ITGB1 (0.38) | — | |
| SCHEMBL1273110 | 0.83 | NOS1 (0.38) | — | |
| SCHEMBL13484370 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022132686-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| EP-3331528-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8039638-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8039638-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20100069353-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20100069353-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2008067644-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |